Recent studies have shown that in cells lacking BRCA1 mutation, sensitization to treatment with PARP inhibitor can also be achieved in sporadic breast cancers through depletion of BRCA1 due to promoter methylation [21]. The gene discussed is BRCA1; the disease is breast carcinoma.